Meta‐ and cost‐effectiveness analysis of commercial weight loss strategies
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objective: To estimate the incremental cost‐effectiveness of clinically proven nonsurgical commercial weight loss strategies for those with BMIs between 25 and 40. Methods: We performed a systematic literature review to identify randomized controlled trials of commercially available weight loss studies of at least 1 year in duration. Using the results of these trials and publicly available cost data, we quantified the incremental cost per kilogram of weight loss and per quality adjusted life year (QALY) gained. We then use probabilistic sensitivity analyses to quantify uncertainty in our results. Results: Based on the literature review, two lifestyle programs (Weight Watchers and Vtrim), one meal replacement program (Jenny Craig), and three pharmaceutical products (Qsymia, Lorcaserin, and Orlistat) were included in the analysis. Average cost per kilogram of weight lost ranged from $155 (95% CI: $110‐$218) for Weight Watchers to $546 (95% CI: $390‐$736) for Orlistat. The incremental cost per QALY gained for Weight Watchers and Qsymia was $34,630 and $54,130, respectively. All other interventions were prohibitively expensive or inferior in that weight loss could be achieved at a lower cost through one or a combination of the other strategies. Conclusions: Results suggest that, in the absence of other considerations and at current market prices, Weight Watchers and Qsymia represent the two most cost‐effective strategies for nonsurgical weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Metformin, an oral diabetic medication, has evidence of weight loss but is not approved for weight loss alone (59).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 5×
“The strategy must also be currently available in the United States.”
BackgroundInfluentialDansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726 · cited 2×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Quantification of the effect of energy imbalance on bodyweight
Hall, K. D., Sacks, G., Chandramohan, D., Chow, C. C., Wang, Y. C., Gortmaker, S. L., & Swinburn, B. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60812-x · Cited by 1,165
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147 · cited 2×
“This is a significant limitation given that weight loss medications and programs are viable substitutes in many circumstances and because resource allocation decisions should be made on the basis of incremental, as opposed to average, costs and benefits, when one is considering a choice between alternative treatment o…”
BackgroundMethodGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States
Tsai, A. G., & Wadden, T. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00012 · Cited by 815 · cited 5×
“2) 546 (390-736) Lorcaserin 2 3 10 mg 1,743 (1,311-2,165) 3.”
BackgroundMethodInfluentialAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Braithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815c31a7 · Cited by 579
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 5×
“The strategy must also be currently available in the United States.”
BackgroundInfluentialOrlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367 · cited 1×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314 · cited 1×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
A Randomized Controlled Trial of a Commercial Internet Weight Loss Program
Womble, L. G., Wadden, T. A., McGuckin, B. G., Sargent, S. L., Rothman, R. A., & Krauthamer‐Ewing, E. S. (2004) · Obesity Research · doi:10.1038/oby.2004.124 · Cited by 247 · cited 1×
“eDiets was excluded as it was found to be no more effective than a control intervention (46).”
BackgroundGold, B. C., Burke, S., Pintauro, S., Buzzell, P., & Harvey‐Berino, J. (2007) · Obesity · doi:10.1038/oby.2007.520 · Cited by 212
Rock, C. L., Flatt, S. W., Sherwood, N. E., Karanja, N., Pakiz, B., & Thomson, C. A. (2010) · JAMA · doi:10.1001/jama.2010.1503 · Cited by 173 · cited 1×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151 · cited 5×
“The strategy must also be currently available in the United States.”
BackgroundInfluentialIncremental cost-effectiveness of a collaborative care intervention for panic disorder
KATON, W., RUSSO, J., SHERBOURNE, C., B. STEIN, M., CRASKE, M., FAN, M.-Y., & ROY-BYRNE, P. (2006) · Psychological Medicine · doi:10.1017/s0033291705006896 · Cited by 93
Effect of orlistat on cardiovascular disease risk in obese adults
Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D., Welborn, T. A., & Caterson, I. D. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00467.x · Cited by 81
Ruof, J., Golay, A., Berne, C., Collin, C., Lentz, J., & Maetzel, A. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802925 · Cited by 40 · cited 3×
“The Orlistat studies report ACERs ranging between US $23,290 and US $102,000 per QALY [converted to USD (62)] (63-76).”
BackgroundWeight Loss With Self-help Compared With a Structured Commercial Program: A Randomized Trial
Heshka, S., Anderson, J. W., Atkinson, R. L., Greenway, F. L., Hill, J. O., Phinney, S. D., Kolotkin, R. L., Miller-Kovach, K., & Pi-Sunyer, F. X. (2003) · JAMA · doi:10.1001/jama.289.14.1792 · Cited by 7 · cited 1×
“In total, 27 studies were identified, 3 for Weight Watchers (n 5 1,355) (10,19,20), 1 for Vtrim (n 5 124) (9), 2 for Jenny Craig (n 5 512) (21,22), 3 for Lorcaserin (n 5 7,789) (23), 17 for Orlistat (n 5 10,875) (24-40), and 1 for Qsymia (n 5 2,487) (13).”
Cited by
Efficacy of Commercial Weight-Loss Programs: An Updated Systematic Review
Gudzune, K. A., Doshi, R. S., Mehta, A. K., Chaudhry, Z. W., Jacobs, D. K., Vakil, R. M., Lee, C. J., Bleich, S. N., & Clark, J. M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2238 · Cited by 325
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Strategies to reduce attrition in weight loss interventions: A systematic review and meta‐analysis
Pirotta, S., Joham, A., Hochberg, L., Moran, L., Lim, S., Hindle, A., & Brennan, L. (2019) · Obesity Reviews · doi:10.1111/obr.12914 · Cited by 45
“A lack of funding further limits the access of at‐risk individuals to needed health care programmes.(11) To date, literature has identified participant characteristics and predictors (eg, psychological and physical barriers) that may lead to attrition(12); however, none have investigated the implications of programme…”
BackgroundNonsurgical weight loss interventions: a systematic review of systematic reviews and meta-analyses
Twells, L. K., Harris Walsh, K., Blackmore, A., Adey, T., Donnan, J., Peddle, J., Ryan, D., Farrell, A., Nguyen, H., Gao, Z., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13320 · Cited by 33
Commercial weight loss programs in the management of obesity: an update.
Laudenslager, M., Chaudhry, Z. W., Rajagopal, S., Clynes, S., & Gudzune, K. A. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00428-y · Cited by 25
Metadata
- Authors
- Finkelstein, E. A., & Kruger, E.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2014-06-24
- Volume
- 22
- Issue
- 9
- Pages
- 1942-1951
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1644939315
- Cited by
- 147
- References
- 26
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.